Kashif Ahmed, MD
Family Medicine · McDonough, GANPI 1023227030
Payments from drug & device makers
Across 465 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AbbVie$1K
- AstraZeneca$782
- Kowa Pharmaceuticals America, Inc.$759
- Novo Nordisk$709
- Boehringer Ingelheim$589
- plus $3K from 27 others
What the payments were for
- Food & beverage$8,03499%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 73 | $1,193 |
| AbbVie(2 entities) | 79 | $1,186 |
| AstraZeneca | 47 | $782 |
| Kowa Pharmaceuticals America, Inc. | 43 | $759 |
| Novo Nordisk | 44 | $709 |
| Boehringer Ingelheim | 26 | $589 |
| Pfizer | 18 | $374 |
| Abbott | 16 | $286 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $281 |
| Shield Therapeutics Inc | 10 | $205 |
| Merck | 12 | $190 |
| Amgen | 9 | $189 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $184 |
| Sanofi-aventis U.S. LLC | 9 | $172 |
| GSK | 8 | $167 |
| Bayer | 6 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $102 |
| Exact Sciences | 4 | $92 |
| Esperion Therapeutics, Inc. | 5 | $87 |
| Corcept Therapeutics | 2 | $59 |
| Kyowa Kirin, Inc. | 3 | $59 |
| Insulet Corporation | 2 | $46 |
| Amarin Pharma, Inc. | 2 | $38 |
| Medline Industries LP | 2 | $34 |
| Ultragenyx Pharmaceutical Inc. | 2 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Novartis | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Dexcom, Inc. | 1 | $13 |
How this compares
$8,085 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 166 | $188,049 |
| OzempicSemaglutide | 117 | $180,008 |
| MounjaroTirzepatide | 49 | $90,271 |
| RybelsusSemaglutide | 42 | $65,328 |
| LinzessLinaclotide | 39 | $57,024 |
| EliquisApixaban | 34 | $46,051 |
| FarxigaDapagliflozin Propanediol | 53 | $44,394 |
| JanuviaSitagliptin Phosphate | 41 | $43,556 |
| JanumetSitagliptin Phos/Metformin Hcl | 31 | $35,417 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $21,728 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $19,798 |
| TradjentaLinagliptin | 16 | $16,464 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $13,704 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $10,823 |
| MyrbetriqMirabegron | 14 | $7,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $709 | $245,336159 claims |
| Boehringer IngelheimJardiance, Tradjenta | $589 | $204,513182 claims |
| MerckJanuvia, Janumet, Janumet Xr | $190 | $98,77187 claims |
| Lilly USA, LLCMounjaro, Humalog Mix 75-25 | $1,193 | $92,85561 claims |
| AbbVieLinzess | $1,186 | $57,02439 claims |
| PfizerEliquis | $374 | $46,05134 claims |
| AstraZenecaFarxiga | $782 | $44,39453 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $167 | $32,55146 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $7,37714 claims |
| Sanofi-aventis U.S. LLCLantus | $172 | $1,48412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in McDonough
- John VuMcDonough$376K
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.